Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Two major drug companies have paused clinical trials of CAR-T therapies following patient deaths.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: wgy.iheart.com · EMJ · Seeking Alpha · STAT · BioSpace.
How this dossier is built: methodology · AI policy · corrections.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
Novartis and Bristol Myers have halted trials of their CAR-T cell therapies. The pause follows three patient deaths in Novartis trials and unspecified safety events in Bristol Myers trials. The European Medicines Journal and BioSpace name Novartis' halted trials as eight in number. The Wall Street Journal is cited as the source for the number of patient deaths in Novartis trials.
STAT News mentions the pause in trials alongside other pharmaceutical news. The pause in trials is due to safety concerns. Novartis halted trials after three patient deaths. Bristol Myers followed suit after unspecified safety events.
The specific nature of these events is not detailed in coverage. The exact number of patients affected and the specific safety events leading to the pause are not specified. The trials that have been paused are not named. The status of other CAR-T cell therapy trials by these companies is not mentioned.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
The reporting (5)
- Autoimmune Drug Trials Halted Following Patient Deaths wgy.iheart.com · 1d ago
- Novartis halts eight CAR-T cell therapy trials after deaths EMJ · 1d ago
- Novartis halts autoimmune CAR-T trials following three patient deaths: WSJ (NVS:NYSE) Seeking Alpha · 1d ago
- Pharmalittle: We're reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more STAT · 1d ago
- Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events BioSpace · 1d ago
Questions people are asking
Which companies have paused CAR-T cell therapy trials?
Novartis and Bristol Myers have paused CAR-T cell therapy trials.
Why were the trials paused?
The trials were paused due to safety concerns, including patient deaths and unspecified safety events.
How many trials has Novartis paused?
Novartis has paused eight CAR-T cell therapy trials.
Topics
Related trends
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk's investors are watching closely as competitors encroach on the company's dominance in the weight-loss drug market.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares rose on September 1 after a new multiple sclerosis drug met its primary goals in late-stage trials.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are poised to announce new pricing deals, potentially saving Americans billions.
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
Novartis’ IL‑6 antibody cuts inflammation markers for half a year in kidney disease trial
I lost the weight on a GLP-1
Men’s weight‑loss drugs face a double‑edge of stigma and rebound fears as GLP‑1 use spikes.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.